Chiusura precedente | 11,83 |
Aperto | 11,82 |
Denaro | 12,04 x 900 |
Lettera | 13,16 x 1800 |
Min-Max giorno | 11,79 - 12,67 |
Intervallo di 52 settimane | 9,59 - 73,03 |
Volume | |
Media Volume | 1.688.709 |
Capitalizzazione | 864,191M |
Beta (5 anni mensile) | 2,06 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -2,73 |
Prossima data utili | 02 ago 2022 - 08 ago 2022 |
Rendimento e dividendo (forward) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 32,23 |
TUEBINGEN, Germany and HOUSTON and CAMBRIDGE, Mass., June 07, 2022 (GLOBE NEWSWIRE) -- Immatics N.V. (Nasdaq: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Editas Medicine, Inc. (Nasdaq: EDIT, “Editas Medicine”), a leading genome editing company, today announced that the two companies have entered into a strategic research collaboration and licensing agreement to combine gamma-delta T cell a
CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Company’s newly appointed President and Chief Executive Officer, Gilmore O’Neill, M.B., M.M.Sc. As previously announced, Dr. O’Neill joined the Company on June 1, 2022, in his new role. In connection with Dr. Gilmore’s appointment, the Editas Medicine Board of Directors approved a stock option grant to Dr. O’Neill as an
SLEEK results in highly efficient multi-transgene knock-in and enables tunability of transgene expression Double knock-in iNK cells demonstrate strong tumor killing effect and prolonged in vivo persistence in an ovarian cancer mouse model CAMBRIDGE, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, will present data later today on its SLEEK (SeLection by Essential- gene Exon Knock-in) gene editing technology during the New Gene Editin